within Pharmacolibrary.Drugs.ATC.J;

model J01DD02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0143,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0057,
    k12             = 11.2,
    k21             = 11.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DD02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ceftazidime is a third-generation cephalosporin antibiotic used to treat a wide range of bacterial infections, including serious infections such as pneumonia, urinary tract infections, and sepsis. It is particularly effective against Gram-negative bacteria and is commonly used in hospital settings. Ceftazidime is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single intravenous dose.</p><h4>References</h4><ol><li><p>van Duin, D, &amp; Bonomo, RA (2016). Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 63(2) 234–241. DOI:<a href=&quot;https://doi.org/10.1093/cid/ciw243&quot;>10.1093/cid/ciw243</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27098166/&quot;>https://pubmed.ncbi.nlm.nih.gov/27098166</a></p></li><li><p>Papich, MG, et al., &amp; Enomoto, H (2022). Ceftazidime pharmacokinetics in dogs after intravenous injection and delivered with the RxActuator Mini-Infuser infusion pump. <i>Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)</i> 32(5) 608–615. DOI:<a href=&quot;https://doi.org/10.1111/vec.13205&quot;>10.1111/vec.13205</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35522422/&quot;>https://pubmed.ncbi.nlm.nih.gov/35522422</a></p></li><li><p>Al Jalali, V, et al., &amp; Zeitlinger, M (2023). Plasma and intraperitoneal pharmacokinetics of ceftazidime/avibactam in peritoneal dialysis patients. <i>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</i> 29(9) 1196.e1–1196.e7. DOI:<a href=&quot;https://doi.org/10.1016/j.cmi.2023.06.002&quot;>10.1016/j.cmi.2023.06.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37301439/&quot;>https://pubmed.ncbi.nlm.nih.gov/37301439</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DD02;
